Clinical Trial

Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors \>55 years old with chemotherapy \>5 years ago. The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-07-13; most recent amendment 2025-05-26.
Status change: Not Yet Recruiting → Recruiting 2021-08-03
Trial Details
NCT Number NCT04962711
Lead Sponsor Baker Heart and Diabetes Institute
Conditions Heart Failure
Enrollment 685 participants
Start Date 2023-03-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-31